National Starch Food Innovation, part of the Ingredion group of companies, has confirmed that health claims for its ingredients Hi-maize 260 resistant starch and Sustagrain wholegrain barley - previously granted a positive opinion from EFSA - have now been approved by the European Commission.
- Hi-maize resistant starch can be used to support blood sugar management positioning with the commission authorising the claim “replacing digestible starches with resistant starch contributes to a reduction in the blood glucose rise after a meal.”
- The claims for Sustagrain wholegrain barley recognise that the ingredient contributes to “an increase in faecal bulk,” (digestive health claim) “the maintenance of healthy cholesterol levels” (heart health claim) and “the maintenance of healthy blood sugar levels” (blood sugar management claim).
Julie Scott, European regulatory manager, National Starch Food Innovation, said: “These health claims were among a relatively small number that were approved by the European Commission on 25 May 2012. Indeed, 1600 other claims were rejected, demonstrating the strength of science and clinical data needed to succeed in the European regulatory landscape today.
“By ensuring the scientific integrity of all health claims, the EFSA rulings will bring clarity to consumers’ purchasing decisions, giving them the peace of mind that a product will do exactly what on-pack messaging says it will.”
Source: Ingredion group